Silence Therapeutics Plc Stock Performance
| SLN Stock | USD 6.45 0.15 2.27% |
The entity has a beta of 1.86, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Silence Therapeutics will likely underperform. At this point, Silence Therapeutics PLC has a negative expected return of -1.38%. Please make sure to validate Silence Therapeutics' information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Silence Therapeutics PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Silence Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 2.33 | Five Day Return (19.02) | Year To Date Return (64.42) | Ten Year Return (66.15) | All Time Return (66.15) |
1 | Silence Therapeutics Sees Large Volume Increase - MarketBeat | 09/25/2024 |
2 | Some Shareholders Feeling Restless Over Silence Therapeutics plcs PS Ratio | 10/04/2024 |
3 | Silence Therapeutics Insider Ups Holding During Year | 11/13/2024 |
4 | Silence Therapeutics Zerlasiran Has Competitive Concerns Analyst | 11/19/2024 |
5 | SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels | 11/20/2024 |
6 | Redmile Group LLC Sells 114,979 Shares of Silence Therapeutics plc - MarketBeat | 12/05/2024 |
7 | Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology Annual Meeting | 12/09/2024 |
8 | Silence Therapeutics Given Buy Rating at Chardan Capital | 12/12/2024 |
| Begin Period Cash Flow | 54.8 M |
Silence |
Silence Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,823 in Silence Therapeutics PLC on September 14, 2024 and sell it today you would lose (1,178) from holding Silence Therapeutics PLC or give up 64.62% of portfolio value over 90 days. Silence Therapeutics PLC is generating negative expected returns assuming volatility of 6.2438% on return distribution over 90 days investment horizon. In other words, 55% of stocks are less volatile than Silence, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Silence Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Silence Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Silence Therapeutics PLC, and traders can use it to determine the average amount a Silence Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2214
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SLN |
Estimated Market Risk
| 6.24 actual daily | 55 55% of assets are less volatile |
Expected Return
| -1.38 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Silence Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Silence Therapeutics by adding Silence Therapeutics to a well-diversified portfolio.
Silence Therapeutics Fundamentals Growth
Silence Stock prices reflect investors' perceptions of the future prospects and financial health of Silence Therapeutics, and Silence Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silence Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (2.24) % | ||||
| Operating Margin | (30.64) % | ||||
| Current Valuation | 189.45 M | ||||
| Shares Outstanding | 47.21 M | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 19.78 X | ||||
| Revenue | 25.38 M | ||||
| Gross Profit | 6.62 M | ||||
| EBITDA | (49.78 M) | ||||
| Net Income | (50.31 M) | ||||
| Cash And Equivalents | 51.56 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 272 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.76 X | ||||
| Book Value Per Share | 0.43 X | ||||
| Cash Flow From Operations | (39.35 M) | ||||
| Earnings Per Share | (1.76) X | ||||
| Market Capitalization | 354.11 M | ||||
| Total Asset | 93.82 M | ||||
| Retained Earnings | (304.61 M) | ||||
| Working Capital | 63.25 M | ||||
About Silence Therapeutics Performance
By examining Silence Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Silence Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Silence Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (658.15) | (625.25) | |
| Return On Tangible Assets | (0.50) | (0.53) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (2.54) | (2.41) |
Things to note about Silence Therapeutics PLC performance evaluation
Checking the ongoing alerts about Silence Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Silence Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Silence Therapeutics generated a negative expected return over the last 90 days | |
| Silence Therapeutics has high historical volatility and very poor performance | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 25.38 M. Reported Net Loss for the year was (50.31 M) with profit before taxes, overhead, and interest of 6.62 M. | |
| Silence Therapeutics PLC has about 51.56 M in cash with (39.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Roughly 63.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Silence Therapeutics Given Buy Rating at Chardan Capital |
- Analyzing Silence Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silence Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Silence Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Silence Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silence Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Silence Therapeutics' stock. These opinions can provide insight into Silence Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Revenue Per Share 0.429 | Quarterly Revenue Growth (0.93) | Return On Assets (0.22) | Return On Equity (0.64) |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.